Affimed Nv

AFMD

2.03

+0.03

+1.5%

Please Login or Register

Login|Register FREE

Stock Price
Open: 2.05
Prev. Close: 2.00
Low/Hi: 1.95 - 2.05
52-Week: 1.15 - 2.85
Volumes
Equity: 169,148
90-Day Avg: 680,204
Option: 11
90-Day Avg: 76
Volatility
Todays Stock Vol: 60.9
20-Day (HV): 83.2
52-Week (HV): 80.5
30-Day IV: 59.2 -5.1
IV Pct Rank: 3% Subdued
Fundamental
Div. Yield:
Earnings: 18-May (Est.)
P/E Ratio:
Market Cap: 124.8 M
Short Int Pct: 0.0%
Pct Held By Inst.: 62.2%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About AFMD

Affimed (AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights.
Primary Exchange: NASDAQ

Wait, Before You Leave...

Want to Know More About AFMD Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon